SCHEMBL2572183

SCHEMBL2572183

CN(Cc1ccc(Cl)cc1Cl)c1ccccc1CC=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYCR1 P32322 1/20 0.43
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP2D6 P10635 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TBXA2R P21731 1/20 0.38
PTGFR P43088 1/20 0.38
PTGER3 P43115 1/20 0.38
PTGER2 P43116 1/20 0.38
PTGIR P43119 1/20 0.38
PTGDR Q13258 1/20 0.38
HTT P42858 3/20 0.37
CYP19A1 P11511 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2572180 0.76 FSCN1 (0.43) PYCR1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL29439097 0.75 IDO1 (0.54) CYP1A2CYP3A4CYP2C9CYP2C19TDP1
SCHEMBL895205 0.75 IDO1 (0.54) CYP1A2CYP3A4CYP2C9CYP2C19TDP1
SCHEMBL11003393 0.73 PYCR1 (0.51) PYCR1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL22047936 0.71 PYCR1 (0.53) PYCR1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL1254040 0.70 ATP4A (0.44) CYP3A4CYP2D6TDP1L3MBTL1ALDH1A1
SCHEMBL6141524 0.70 TAAR1 (0.37) CYP2C19CYP2D6ALDH1A1MEN1KMT2A
SCHEMBL27416094 0.70 ATM (0.44) ATML3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL16553471 0.69 PYCR1 (0.61) PYCR1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL16795582 0.68 MAOA (0.43) PYCR1CYP1A2CYP3A4CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2384318-A2 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS Ardelyx, Inc. (US) 2011-11-09 EP disclosed
WO-2010078449-A2 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2010-07-08 WO disclosed